ZA201304237B - Use of laquinimod for reducing fatigue,improving functional status,and improving quality of life in multiple sclerosis patients - Google Patents

Use of laquinimod for reducing fatigue,improving functional status,and improving quality of life in multiple sclerosis patients

Info

Publication number
ZA201304237B
ZA201304237B ZA2013/04237A ZA201304237A ZA201304237B ZA 201304237 B ZA201304237 B ZA 201304237B ZA 2013/04237 A ZA2013/04237 A ZA 2013/04237A ZA 201304237 A ZA201304237 A ZA 201304237A ZA 201304237 B ZA201304237 B ZA 201304237B
Authority
ZA
South Africa
Prior art keywords
improving
laquinimod
life
multiple sclerosis
functional status
Prior art date
Application number
ZA2013/04237A
Other languages
English (en)
Inventor
Nora Tarcic
Dan Bar-Zohar
Dina Kofler
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46162796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201304237(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of ZA201304237B publication Critical patent/ZA201304237B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA2013/04237A 2010-12-07 2013-06-10 Use of laquinimod for reducing fatigue,improving functional status,and improving quality of life in multiple sclerosis patients ZA201304237B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42074210P 2010-12-07 2010-12-07
US201161542996P 2011-10-04 2011-10-04
PCT/US2011/063460 WO2012078591A1 (en) 2010-12-07 2011-12-06 Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients

Publications (1)

Publication Number Publication Date
ZA201304237B true ZA201304237B (en) 2014-08-27

Family

ID=46162796

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2013/04237A ZA201304237B (en) 2010-12-07 2013-06-10 Use of laquinimod for reducing fatigue,improving functional status,and improving quality of life in multiple sclerosis patients

Country Status (19)

Country Link
US (1) US20120142730A1 (OSRAM)
EP (1) EP2648732A4 (OSRAM)
JP (2) JP2013544887A (OSRAM)
KR (1) KR20130124518A (OSRAM)
CN (1) CN103260624B (OSRAM)
AU (2) AU2011338647A1 (OSRAM)
BR (1) BR112013014061A2 (OSRAM)
CA (1) CA2820586A1 (OSRAM)
CL (1) CL2013001602A1 (OSRAM)
EA (1) EA201390827A1 (OSRAM)
IL (1) IL250726A0 (OSRAM)
MX (1) MX2013006464A (OSRAM)
NZ (1) NZ611628A (OSRAM)
PE (1) PE20140872A1 (OSRAM)
PH (1) PH12013501193A1 (OSRAM)
SG (2) SG10201509831XA (OSRAM)
UA (1) UA111959C2 (OSRAM)
WO (1) WO2012078591A1 (OSRAM)
ZA (1) ZA201304237B (OSRAM)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1937642E (pt) * 2005-10-19 2014-11-25 Teva Pharma Cristais de sódio de laquinimod, e processos para o fabrico dos mesmos
EP2682120B1 (en) 2007-12-20 2016-08-03 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
BR112012002124A2 (pt) * 2009-07-30 2015-09-15 Teva Pharma tratamento da doença de crohn com laquinimode.
DK2467372T3 (en) 2009-08-10 2016-08-22 Teva Pharma TREATMENT OF BDNF-RELATED DISEASES USING LAQUINIMOD
BR112012021905A2 (pt) * 2010-03-03 2015-09-29 Teva Pharma tratamento de nefrite lúpica usando laquinimod
BR112012022187A2 (pt) * 2010-03-03 2015-09-22 Teva Pharma tratamento de artrite reumatóide com a combinação de laquinimod e metotrexato
KR20130092558A (ko) 2010-07-09 2013-08-20 테바 파마슈티컬 인더스트리즈 리미티드 중수소화된 n-에틸-n-페닐-1,2-다이하이드로-4-하이드록시-5-클로로-1-메틸-2-옥소퀴놀린-3-카복스아마이드, 그의 염 및 용도
US8889627B2 (en) 2011-10-12 2014-11-18 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with combination of laquinimod and fingolimod
CN106063787A (zh) 2012-02-03 2016-11-02 泰华制药工业有限公司 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途
AU2013221304B2 (en) 2012-02-16 2017-12-21 Teva Pharmaceutical Industries Ltd. N-ethyl-N-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinoline carboxamide, preparation and uses thereof
TW201350467A (zh) 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
AU2013323131A1 (en) * 2012-09-27 2015-05-07 Teva Pharmaceutical Industries Ltd. Laquinimod and pridopidine for treating neurodegenerative disorders
HK1218865A1 (zh) * 2012-10-12 2017-03-17 Teva Pharmaceutical Industries Ltd. 用於降低多发性硬化症中丘脑损伤的拉喹莫德
EA201590788A1 (ru) 2012-11-07 2015-12-30 Тева Фармасьютикал Индастриз Лтд. Аминные соли лахинимода
CA2900503A1 (en) * 2013-02-15 2014-08-21 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with laquinimod
MX2015010967A (es) 2013-03-14 2015-10-26 Teva Pharma Formulaciones transdermicas de laquinimod.
AU2014236232A1 (en) 2013-03-14 2015-11-05 Teva Pharmaceutical Industries Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof
AU2014364447A1 (en) * 2013-12-20 2016-08-04 Teva Pharmaceutical Industries Ltd. Use of laquinimod to delay Huntington's disease progression
EP3094330A4 (en) * 2014-01-17 2017-09-27 Teva Pharmaceutical Industries Ltd Treatment of crohn's disease using low doses of laquinimod
JP2017514824A (ja) * 2014-04-29 2017-06-08 テバ ファーマシューティカル インダストリーズ リミティド 能力障害度が高い再発寛解型多発性硬化症（ｒｒｍｓ）患者の処置のためのラキニモド
CN107072988A (zh) * 2014-10-16 2017-08-18 诺华股份有限公司 包含辛波莫德和拉喹莫德的用于治疗多发性硬化症的组合
EP3236964A4 (en) 2014-12-22 2018-09-19 Teva Pharmaceuticals International GmbH L-tartrate salt of pridopidine
EP3863628B1 (en) * 2018-10-09 2023-12-27 MediciNova, Inc. Combination of ibudilast and interferon-beta and methods of using same
AU2020316640A1 (en) * 2019-07-22 2022-03-03 Actelion Pharmaceuticals Ltd Methods of treating multiple sclerosis
CN110688373A (zh) * 2019-09-17 2020-01-14 杭州绿度信息技术有限公司 一种基于逻辑回归的offset方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1797109T3 (en) * 2004-09-09 2016-04-11 Yeda Res & Dev MIXTURES OF POLYPEPTIDES, compositions containing them and methods for their preparation, and uses thereof
US20060205822A1 (en) * 2004-12-22 2006-09-14 Forest Laboratories, Inc. 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
US9168286B2 (en) * 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
NZ573846A (en) * 2006-06-12 2012-01-12 Teva Pharma Stable laquinimod preparations
EP2680009A1 (en) * 2007-02-08 2014-01-01 Biogen Idec MA Inc. Nrf2 screening assays and related methods and compositions
US20100322900A1 (en) * 2009-06-19 2010-12-23 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with laquinimod

Also Published As

Publication number Publication date
SG190449A1 (en) 2013-07-31
MX2013006464A (es) 2013-07-29
EP2648732A4 (en) 2014-04-30
CL2013001602A1 (es) 2013-10-25
CN103260624A (zh) 2013-08-21
CA2820586A1 (en) 2012-06-14
CN103260624B (zh) 2015-06-03
AU2011338647A8 (en) 2013-09-05
NZ611628A (en) 2015-06-26
BR112013014061A2 (pt) 2016-09-13
SG10201509831XA (en) 2015-12-30
WO2012078591A1 (en) 2012-06-14
JP2013544887A (ja) 2013-12-19
JP2017095476A (ja) 2017-06-01
WO2012078591A8 (en) 2012-08-02
PE20140872A1 (es) 2014-08-09
KR20130124518A (ko) 2013-11-14
AU2011338647A1 (en) 2013-07-04
UA111959C2 (uk) 2016-07-11
IL250726A0 (en) 2017-04-30
AU2017202055A1 (en) 2017-04-20
US20120142730A1 (en) 2012-06-07
PH12013501193A1 (en) 2013-07-15
EA201390827A1 (ru) 2013-12-30
EP2648732A1 (en) 2013-10-16

Similar Documents

Publication Publication Date Title
IL250726A0 (en) Use of lequinimod to reduce fatigue, improve function and improve quality of life in multiple sclerosis patients
IL252699A0 (en) Use of lequinimod to treat multiple sclerosis
ZA201403378B (en) Treatment of multiple sclerosis with combination of laquinimod and fingolimod
GB2481911B (en) Hard face structure, body comprising same and method for making same
EP2686514B8 (en) Integral wear pad and method
PL2685994T3 (pl) Bakterie probiotyczne wykazujące aktywność przeciwutleniającą i ich zastosowanie
ZA201401217B (en) Treatment of multiple sclerosis with combination of laquinimod and interferon-beta
AP2014007805A0 (en) Substituted benzaldehyde compounds and methods fortheir use in increasing tissue oxygenation
EP2716669A4 (en) METHOD OF MODIFYING SURFACE AND ELASTIC BODY HAVING MODIFIED SURFACE
SG11201401949YA (en) Nadph oxidase 4 inhibitors and use thereof
EP2731601A4 (en) EOSINOPHILIC PEROXIDASE COMPOSITIONS AND METHOD FOR THEIR USE
ZA201304235B (en) Oprf/i agents and their use in hospitalized and other patients
GB0920258D0 (en) New medical agents and use thereof
IL232174A0 (en) Preparations containing a salt of a sodium channel inhibitor and their uses
PT2696871T (pt) Aclidínio para utilização na melhoria da qualidade do sono em pacientes respiratórios¿
HUE044588T2 (hu) Fitoekdizonok elhízott és szarkopéniás emlõsök izomzat-minõségének javítására szolgáló alkalmazásra
HK1188950A (en) Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients
EP2781227A4 (en) ELEMENT FOR USE IN A TEXTILE GENERATION, MANUFACTURING METHOD AND INK
HK1193751A (en) Aclidinium for use in improving the quality of sleep in respiratory patients
EG27140A (en) Preparation and characterization of metformin as insulin resistant reducing agents for type ii diabetes
IL215573A0 (en) Scouring sponge with symbol of " meet" , " milk" and " parve"
TWM402465U (en) Mouse pad for use in wheelchair